Welcome! We regret to inform you that the Injury Board National News Desk has been discontinued. Feel free to browse around and enjoy our previously published articles, or visit The Injury Blog Network for the latest in personal injury news.

Avastin Faces Uphill Climb as Breast Cancer Drug

Posted by Jane Akre
Wednesday, February 13, 2008 10:04 AM EST
Category: Major Medical, Protecting Your Family
Tags: Avastin, FDA and Prescription Drugs, Defective Drugs

Avastin shows good results for treating breast cancer but may not be good enough for FDa approval.

Image: downtown Louisville, KY

LEARN MORE

So far Avastin, a drug used to slow the growth of colorectal and lung cancers, is have a tough time convincing regulators its use should be expanded to treat breast cancer.

Maker Genentech Inc. is trying though.  

A second study is reported to show that Avastin slows the growth of breast-cancer tumors when combined with chemotherapy. This study was sponsored by Genentech's major shareholder, Roche Holding AG. and is a bid to expand its use, therefore expand profits.

February 23rd, the FDA will decide whether Avastin can be used for breast cancer patients, for whom it is already being used off-label.  That approval could expand profits which  totaled $2.3 billion in 2007.

But it has not been an easy climb. The drug is used to treat breast cancer that has spread or metastatic breast cancer. An earlier study of 722 women showed that Avastin combined with the drug Taxol appeared to stop cancer progression by 11.3 months. That is five months longer than Taxol alone.

But the drug combination did nothing to extend a woman's survival and there were side effects from Avastin such as hypertension, blood clots and bowel perforation as well as additional deaths.

Last December, an FDA panel voted against recommending Avastin for treating breast cancer.  

Upon news of the latest positive trial results, shares rose in premarket trading Wednesday for Genentech 2.6 percent to $71.70 a share. However analysts say the drug has only a 40 to 50 percent chance of gaining FDA approval. 

The FDA approved fewer drugs in 2007- 69 in all. That number represents a 26 percent drop from the previous year even as big pharmaceutical companies face a rash of patent expirations. Analysts say that facing criticism for being too easy on Big Pharma, the FDA is raising the bar on drug approvals. #


No Comments

Comments for this article are closed.

About the National News Desk

Our mission is to seek the complete truth and provide a full and fair account of the events and issues that surround personal safety, accident prevention, and injury recovery.  We are committed to serving the public with honesty and integrity in these efforts.

Hurt in an accident? Contact an Injury Board member

Subscribe to Blog Updates

Enter your email address if you would like to receive email notifications when comments are made on this post.

Email address

Subscribe

RSS Feed

Add the National News Desk to your favorite RSS reader

Add to Google Reader Add to myYahoo Add to myMSN Add to Bloglines Add to Newsgator Add to Netvibes Add to Pageflakes